Clinical trials: Acute Moderate-to-severe Pain
Bronchiolitis
Peak Tidal Inspiratory Flow in Infants With Moderate to Severe Acute Viral Bronchiolitis
This aim of this study is to measure the peak tidal inspiratory flow (PTIF), using spirometry, in young infants with moderate to severe acute viral bronchiolitis (AVB).
- Trial name
- DEBIB (NCT03298217)
- Testing
- Measurement of the peak tidal inspiratory flow (PTIF)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier
Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection
Fluvoxamine for Adults With Mild to Moderate COVID-19
This clinical trial aims to determine if fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma-1 receptor, can be used in mild to moderate COVID-19 to prevent the progression to severe COVID-19.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus Infection, Mild to Moderate COVID-19
- Trial name
- NCT04711863
- Testing
- Fluvoxamine
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Asan Medical Center
Arthritis, Gouty
Celebrex In Acute Gouty Arthritis Study
This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation…
- Trial name
- NCT00549549
- Testing
- Indomethacin, Celecoxib
- Where
- 81 sites in United States, Canada and 10 more
- Volunteers
- 402 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Covid-19
Antioxidant Therapy for COVID-19 Study
Finding effective strategies to treat or prevent the novel coronavirus disease that started in 2019 (COVID-19) is a global public health priority.
- Trial name
- GSHSOD-COVID (NCT04466657)
- Testing
- Antioxidation Therapy, Standard of Care
- Where
- 11 sites in Nigeria
- Sponsor
- Obafemi Awolowo University
Cyclic Vomiting Syndrome
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
- Trial name
- NCT04645953
- Testing
- 3mg AZ-010, 1mg AZ010
- Where
- 18 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Respiratory Distress Syndrome, Adult
Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome
During the acute respiratory distress syndrome (ARDS), patients' response to positive end-expiratory pressure (PEEP) is variable according to different degrees of lung recruitability.
- Trial name
- IPERPEEP (NCT04012073)
- Testing
- Invasive Mechanical ventilation, Neuromuscular Blocking Agents, Prone positioning
- Where
- 10 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma
CAR T-cell Therapy in Patients With Renal Dysfunction
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
- Conditions
- Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT05909059
- Testing
- Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Pancreatitis, Acute
Safety and Tolerability of Pirfenidone in Acute Pancreatitis
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis.
- Trial name
- NCT05350371
- Testing
- Pirfenidone Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
COPD, AECOPD
Home Oscillatory Positive Expiratory Pressure - Aerobic Exercise Rehabilitation Study
The goal of this clinical trial is to evaluate the feasibility and effectiveness of home OPEP therapy and aerobic exercise training in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who are at high…
- Trial name
- HOPE-AERO (NCT06970054)
- Testing
- OPEP, Aerobic Exercise
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Sir Run Run Shaw Hospital
Acute Malnutrition in Infancy (Disorder)
Optimizing Acute Malnutrition Management in Children Aged 6 to 59 Months in Niger (OptIMA Niger)
Acute malnutrition (AM) is a continuum condition, arbitrarily divided into severe and moderate categories (SAM, MAM) which are managed separately, with programs overseen by different agencies with different products and supply…
- Trial name
- NCT04698070
- Testing
- Nutritional Strategy - OptiMA, Nutritional Strategy - ComPAS, National nutritional Strategy (Niger)
- Where
- 4 sites in Niger
- Volunteers
- 2,304 people
- Sponsor
- Alliance for International Medical Action
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Moderate Acute Respiratory Distress Syndrome
Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS
Pathophysiological, experimental and clinical data suggest that an '"ultraprotective" mechanical ventilation strategy may further reduce VILI and ARDS-associated morbidity and mortality.
- Trial name
- SUPERNOVA (NCT02282657)
- Testing
- ECCO2R will be initiated during the 2-hour run-in time, Neuromuscular blocking agents (NMBA), Ventilation
- Where
- Belgium
- Volunteers
- 95 people
- Sponsor
- European Society of Intensive Care Medicine
ARDS (Acute Respiratory Distress Syndrome)
Time-controlled Adaptive Ventilation (TCAV) Compared With Conventional Ventilation in Patients With Moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) Secondary to Community-acquired Pneumonia
ARDS is a pathology with mortality rates reaching 40%. Invasive ventilation, the cornerstone of ARDS management, leads to "ventilation-induced lung injury" (VILI).
- Trial name
- EARLY-TCAV (NCT07679802)
- Testing
- Invasive ventilation with the Time-controlled Adaptative Ventilation settings applied to the Airway Pressure Release Ventilation mode, Volume Control
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Central Hospital, Nancy, France
Acute Respiratory Distress Syndrome
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
China faces major challenges in the ECMO management of patients with moderate-to-severe ARDS, including substantial heterogeneity in clinical practice, low weaning success rates, and high complication rates.
- Trial name
- NCT07726953
- Testing
- Full-Course ECMO Management Pathway, Usual Care
- Where
- 39 sites in China
- Volunteers
- 500 people
- Sponsor
- Southeast University, China
COPD
Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)
Chronic Obstructive Pulmonary Disease (COPD) secondary to biomass exposure constitutes a chronic respiratory condition frequently excluded from large clinical trials.
- Trial name
- EMERAL (NCT02473237)
- Testing
- indacaterol, Tiotropium
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- National Institute of Respiratory Diseases, Mexico
Asthma, Acute Asthma
Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.
The purpose of this study is to determine if adding single dose of oral montelukast to the standard treatment of systemic glucocorticoids plus short acting beta-2 agonist for treatment of acute wheezing provide additional…
- Trial name
- NCT01304901
- Testing
- montelukast 4 mg granule
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Kecioren Education and Training Hospital
Postoperative Pain
Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients
This is a randomized, double-blind, multicenter, fixed dose factorial study of Q8003 12 mg/8 mg and Q8003 6 mg/4 mg versus its individual morphine sulfate and oxycodone hydrochloride components for the management of acute…
- Trial name
- NCT00831051
- Testing
- Q8003, Morphine sulfate, Oxycodone HCl
- Where
- 6 sites in United States
- Volunteers
- 197 people
- Sponsor
- QRxPharma Inc.
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.
COVID 19 Disease, Mild to Moderate COVID 19 Disease
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease and low risk of disease progression (the "ACLR8-LR" study).
- Conditions
- COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2, Infectious Disease
- Trial name
- NCT05947812
- Testing
- Tafenoquine Oral Tablet
- Volunteers
- 148 people
- Sponsor
- 60P Australia Pty Ltd